Kristi RPh - Neximmune President CEO
| NEXI Stock | | | USD 0.0001 0.00 0.00% |
CEO
Kristi RPh is President CEO of Neximmune
| Age | 61 |
| Phone | 301 825 9810 |
| Web | https://www.neximmune.com |
Neximmune Management Efficiency
The company has return on total asset
(ROA) of
(0.6971) % which means that it has lost $0.6971 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.9648) %, meaning that it created substantial loss on money invested by shareholders. Neximmune's management efficiency ratios could be used to measure how well Neximmune manages its routine affairs as well as how well it operates its assets and liabilities.
Neximmune currently holds 68.81
K in liabilities with Debt to Equity
(D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Neximmune has a current ratio of 6.41, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Debt can assist Neximmune until it has trouble settling it off, either with new capital or with free cash flow. So, Neximmune's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Neximmune sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Neximmune to invest in growth at high rates of return. When we think about Neximmune's use of debt, we should always consider it together with cash and equity.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people. Neximmune [NEXI] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Neximmune Leadership Team
Elected by the shareholders, the Neximmune's board of directors comprises two types of representatives: Neximmune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neximmune. The board's role is to monitor Neximmune's management team and ensure that shareholders' interests are well served. Neximmune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neximmune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Chief Officer | |
| Mathias Oelke, Chief Officer | |
| Chad Rubin, Senior Affairs | |
| Daniel Bednarik, Senior Design | |
| Timothy Stover, Corporate VP | |
| John MBA, Chief Officer | |
| Karen Haslbeck, Head Resources | |
| Jerome MD, Consultant | |
| Matthew Schiller, Head Development | |
| Kristi RPh, President CEO | |
Neximmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Neximmune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Neximmune Pink Sheet
Neximmune financial ratios help investors to determine whether Neximmune Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Neximmune with respect to the benefits of owning Neximmune security.